Abstract
The present study is an attempt to develop a Matrix type transdermal system capable of delivering the selected antidiabetic drug Repaglinide in the desired therapeutic concentration for prolong period. The principle of transdermal drug delivery systems is to deliver drug across epidermis to achieve systemic effect over a prolonged period of time. Because of these attributes, transdermal drug delivery systems offer many advantages such as reduced side effects, improved patient compliance, elimination of first-pass metabolism, and sustained drug delivery. Anti-diabetic drug which is important for the treatment of hyperglycemic disorders. This category of anti-diabetic drugs is rapid and almost completely absorbed from the GIT following oral administration, but undergoes extensive first pass metabolism. Therefore, the peak plasma concentration occurs rapidly and after a single oral dose and bioavailability is 56%, the half-life of elimination is 1 hour in normal subject. Hence, it is required to design a drug delivery system which may deliver anti- diabetic drug Repaglinide in controlled manner for a prolonged period to circumvent the drug related side effects. Considering all these problems associated with oral administration of anti-diabetic drug Repaglinide, attempt has been made to develop transdermal drug delivery system in order to achieve a better release pattern.
References
Chein, Y.W, (1987), In Transdermal Controlled Systemic Medications,Marcel Dekker, Inc N.Y, P. 25-70.
Weadock, K.S, et. Al. (1987) In Transdermal Controlled System medications: CheinY.W.Ed. Marcell Dekker N.Y P. 113.
K D. Tripathi. Insulin, oral hypoglycemic and glucagons, in: Essentials of Medical Pharmacology. 6th edition, Jaypee Brothers Medical Publishers (P) Ltd., New Delhi, 2008, 235.
Moses Robert, 2009, Fixed combination of repaglinide and metformin in management of type 2 diabetes. Diabetes metabolic syndrome and obesity: targets and therapy, 101-9.
Blickle, J.F, 2006, Meglitinide analogues: a review of clinical data focused on recent trials. Diabetes Metab (32),113-20.[View in PubMed]
Gupta, S, Jain, S, 2004, Development of matrix- membrane Transdermal drug delivery system for atenolol. Drug Del. (5), 281-286.[View in PubMed]
Shaila, Lewis, S.Pandey, and Udupa, N, 2006, Design and Evaluation of Matrix type and membrane controlled Transdermal delivery system of Nicotinesuitable for using smoking cessation, IND. Journal.Pharm.Sci., 68(2), 179-184.
Mutalik, S, Udupa, N, Kumar, S, Agarwal, S, Subramanian, G, Ranjith, AK. 2006, Glipizide Transdermal systems for diabetes mellitus: Preparation, in vitro and preclinical studies. Life Sci. (79) 1568-1577.
Sankar, V, Benito Johnson, D, Sivanand, V, Raghuraman, S, Velrajan, G, Palaniappan, R, Rajashekar, S, Chandrasekaran, AK. 2003, Design and evaluation of nifedipine Transdermal patches.Ind J Pharma Sci 65(5), 510-5.
Mukherjeea, B, Mahapatraa, S, Guptab, R, Patraa, B, Tiwarib, A, A rorab, P. A 2005, comparison between povidone- ethyl cellulose and povidone-Eudragit Transdermal dexamethasone matrix patches based on in vitro skin permeation. Eur. J. Pharm. Biopharma. (59), 475-483.
Sandip, B, Tiwari, Krishna, Murhty, T, RaveendraPai, M, Pavak, R Mehta, Pasula, B 2003, Chowdary. Controlled release formulation of Tramadol hydrochloride using hydro philic and hydrophobic matrix System. AAPS Pharma SciTech 4(3) Article 31.
Aqil, M, Sultana, Y, Ali, A, 2003, Matrix type Transdermal drug delivery systems of metoprololtratrate: In vitrocharacterization. ActaPharma (53), 119-125. [View in PubMed]
Aqil, M, Ali, A, 2002, Monolithic matrix type Transdermal drug delivery systems of pinacidil monohydrate: in vitro characterization. Eur. J. Pharm. Biopharma. (54), 161-164.[View in PubMed]
Verma, A, Verma, B, Prajapati, S, 2012, Formulation and Evaluation of Transdermal Therapeutic System of matrix type Clonidine Hydrochloride. Der Pharmacia Lettre, 4 (4),1137-1142.
Lewis, S, pandey, S, and Udupa, N, Design and Evaluation of Matrix Type and membrane controlled transdermal delivery system of nicotine suitable for use in smoking cessation. Indian Journal of Pharmaceutical Sciences 179 -184.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright (c) 2020 Array